| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $458,856 | +15,209 | +87% | $30.17 | 32,671 | 22 Feb 2023 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $93,490 | -2,206 | -6.8% | $42.38 | 30,465 | 22 Feb 2023 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | $404,618 | -9,259 | -30% | $43.70 | 21,206 | 22 Feb 2023 | Direct | F3, F4 |
| holding | PFE | Common Stock | 10,375 | 22 Feb 2023 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -15,209 | -100% | $0.000000* | 0 | 22 Feb 2023 | Common Stock | 15,209 | $30.17 | Direct | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +45,920 | $0.000000 | 45,920 | 23 Feb 2023 | Common Stock | 45,920 | $42.30 | Direct | F5 | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +39,965 | $0.000000 | 39,965 | 23 Feb 2023 | Common Stock | 39,965 | $42.30 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| F5 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| F6 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |